It's not the most glamorous corner of life sciences — but validation, calibration and standardization might be the most essential.
Every measurement in pharmaceutical manufacturing, every reading from a lab instrument, every quality checkpoint in a biologics production line depends on rigorous calibration and validation. Get it wrong, and you're looking at regulatory action, product recalls or worse.
The global market for these services was valued at $2.7 billion in 2024 and is projected to reach $3.9 billion by 2030, growing at a 6.7% CAGR.
What's driving the growth? Three big forces.
First, regulatory pressure keeps intensifying. FDA, EMA and global regulators are tightening requirements for equipment qualification, process validation and data integrity. This isn't discretionary spending — it's mandatory.
Second, the explosion of complex biologics and advanced therapy medicinal products (ATMPs) like cell and gene therapies demands far more rigorous validation than traditional small-molecule drugs. More complexity means more calibration.
Third, digital transformation is reshaping the entire field. AI-driven validation platforms, IoT-enabled smart calibration, digital twins and cloud-based GxP compliance systems are replacing paper-based quality workflows — creating both efficiency gains and new technology investment.
North America leads with 40.5% of the market, with key players including Thermo Fisher, Endress+Hauser, SGS, Transcat, Trescal and Valgenesis.
**Want the full picture?** Download the free overview of our report *Validation, Calibration, and Standardization in the Life Sciences Market* for detailed segmentation, competitive intelligence and technology analysis.
[Download the Free Report Overview →]